牙周治療市場 - 副產品（局部抗生素治療、全身性抗生素治療）、類型（牙齦炎、慢性牙周病、侵襲性牙周病）、配銷通路- 全球預測（2024 - 2032）

在牙周病盛行率上升的推動下，2024年至2032年牙周治療市場規模將以7.7%的複合年成長率成長。根據世界衛生組織 2023 年 3 月發布的口腔健康報告，估計全球約 19% 的成年人口患有嚴重的牙周疾病。口腔衛生不良、吸菸和糖尿病等全身健康問題等因素導致這些疾病的負擔日益加劇。因此，對有效治療解決方案的需求激增，促使對先進牙周治療的開發和實施進行大量投資。

個人化治療計畫的出現是塑造市場的重要趨勢。牙科診斷和患者資料分析的進步使醫生能夠根據患者的個人資料（包括其基因組成、疾病嚴重程度和整體健康狀況）量身定做治療方案。這種向個人化護理的轉變透過滿足患者的特定需求和偏好、改善結果和滿意度來提高治療效果。個人化治療計劃通常結合標靶治療、先進診斷和客製化預防措施，使牙周護理更加有效並以患者為中心。

牙周治療產業根據產品、類型、配銷通路和地區進行分類。

到 2032 年，局部抗生素治療領域將快速成長。這種方法可以進行有針對性的治療，最大限度地減少全身副作用並提高牙周護理的整體效果。局部抗生素製劑和遞送機制（例如控釋系統）的最新進展預計將推動該領域的成長。

到 2032 年，侵襲性牙周病領域將出現良好成長。這種情況需要及時有效的治療干預，以防止嚴重後果，包括牙齒脫落。不斷上升的發病率推動了對這種嚴重牙周炎的先進治療方案的需求。旨在控制疾病進展和促進組織再生的治療對於滿足侵襲性牙周病患者的需求至關重要。

在多種因素的推動下，歐洲牙周治療產業將在 2032 年實現強勁成長。該地區完善的醫療基礎設施和高標準的牙科護理有助於擴大採用先進的牙周治療。歐洲國家的牙周病發生率也不斷上升，促使人們加大對治療解決方案的投資。此外，持續的研發工作正在引入用於疾病管理的創新產品和技術，進一步推動區域市場的成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 牙周病盛行率不斷上升
    • 提高口腔健康意識
    • 老年人口不斷增加
    • 牙科技術進步
  • 產業陷阱與挑戰
    • 對口腔健康的認知與教育有限
    • 嚴格的監理政策
• 成長潛力分析
• 報銷場景
• 監管環境
• 技術景觀
  • 核心技術
  • 鄰近技術
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

• 主要趨勢
• 局部抗生素治療
  • 鹽酸米諾環素
  • 鹽酸多西環素
  • 葡萄糖酸氯己定
  • 甲硝唑苯甲酸鹽
  • 鹽酸四環素
• 全身性抗生素治療
  • 鹽酸米諾環素
  • 鹽酸多西環素
  • 甲硝唑苯甲酸鹽

第 6 章：市場估計與預測：按類型，2021 - 2032

• 主要趨勢
• 牙齦炎
• 慢性牙周病
• 侵襲性牙周病
• 壞死性牙周病
• 其他類型

第 7 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 藥局
• 電子商務

第 8 章：市場估計與預測：按地區分類，2021 - 2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• Align Technology, Inc.
• Bausch Health Companies Inc.
• Cadila Healthcare Ltd.
• Colgate-Palmolive Company
• Danaher Corporation
• Den-Mat Holdings LLC
• Dentsply Sirona
• Dexcel Pharma Technologies Ltd.
• GlaxoSmithKline plc
• Henry Schein, Inc.
• Hoffmann-La Roche Ltd.
• Johnson & Johnson Services, Inc.
• Kaken Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Procter & Gamble Co.
• Straumann Holding AG
• Sunstar Suisse SA
• Teva Pharmaceutical Industries Ltd.
• Zimmer Biomet Holdings, Inc.
• 3M Company

The Periodontal Therapeutics Market size will grow at 7.7% CAGR during 2024-2032, driven by the rising prevalence of periodontal diseases. According to a WHO Oral Health report published in March 2023, severe periodontal ailments are estimated to impact approximately 19% of the global adult population. Factors such as poor oral hygiene, smoking, and systemic health issues like diabetes contribute to the growing burden of these diseases. As a result, there is a surge in demand for effective therapeutic solutions, prompting significant investment in the development and delivery of advanced periodontal treatments.

The emergence of personalized treatment plans is a significant trend shaping the market. Advances in dental diagnostics and patient data analysis are enabling practitioners to tailor treatments based on individual patient profiles, including their genetic makeup, disease severity, and overall health conditions. This shift towards personalized care enhances treatment efficacy by addressing specific needs and preferences of patients, improving outcomes and satisfaction. Personalized treatment plans often incorporate a combination of targeted therapies, advanced diagnostics, and customized preventive measures, making periodontal care more effective and patient centric.

The periodontal therapeutics industry is classified based on product, type, distribution channel, and region.

The local antibiotic therapy segment will grow rapidly through 2032. Local antibiotic therapy involves the direct application of antimicrobial agents to the periodontal pocket to control bacterial infections and reduce inflammation. This approach allows for targeted treatment, minimizing systemic side effects and enhancing the overall effectiveness of periodontal care. Recent advancements in local antibiotic formulations and delivery mechanisms, such as controlled-release systems, are expected to drive growth in this segment.

The aggressive periodontal disease segment will witness decent growth through 2032. Aggressive periodontal disease, characterized by rapid attachment loss and bone destruction, poses a serious challenge to oral health. This condition requires prompt and effective therapeutic interventions to prevent severe consequences, including tooth loss. The increasing incidence rate is driving demand for advanced treatment options tailored to managing this severe form of periodontitis. Therapies aimed at controlling the disease's progression and promoting tissue regeneration are crucial in addressing the needs of patients with aggressive periodontal conditions.

Europe periodontal therapeutics industry will witness robust growth through 2032, driven by a combination of factors. The region's well-established healthcare infrastructure and high standards of dental care contribute to the increasing adoption of advanced periodontal treatments. European countries are also experiencing a rising incidence of periodontal diseases, which is prompting greater investment in therapeutic solutions. Moreover, ongoing R&D efforts are leading to the introduction of innovative products and technologies for disease management, further fueling the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360°synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of periodontal diseases
    • 3.2.1.2 Increasing awareness about oral health
    • 3.2.1.3 Rising geriatric population
    • 3.2.1.4 Technological advancements in dentistry
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Limited awareness and education for oral health
    • 3.2.2.2 Stringent regulatory policies
• 3.3 Growth potential analysis
• 3.4 Reimbursement scenario
• 3.5 Regulatory landscape
• 3.6 Technological landscape
  • 3.6.1 Core technologies
  • 3.6.2 Adjacent technologies
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Local antibiotic therapy
  • 5.2.1 Minocycline hydrochloride
  • 5.2.2 Doxycycline hyclate
  • 5.2.3 Chlorhexidine gluconate
  • 5.2.4 Metronidazole benzoate
  • 5.2.5 Tetracycline hydrochloride
• 5.3 Systemic antibiotic therapy
  • 5.3.1 Minocycline hydrochloride
  • 5.3.2 Doxycycline hyclate
  • 5.3.3 Metronidazole benzoate

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Gingivitis
• 6.3 Chronic periodontal disease
• 6.4 Aggressive periodontal disease
• 6.5 Necrotizing periodontal disease
• 6.6 Other types

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 Drug stores
• 7.5 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Align Technology, Inc.
• 9.2 Bausch Health Companies Inc.
• 9.3 Cadila Healthcare Ltd.
• 9.4 Colgate-Palmolive Company
• 9.5 Danaher Corporation
• 9.6 Den-Mat Holdings LLC
• 9.7 Dentsply Sirona
• 9.8 Dexcel Pharma Technologies Ltd.
• 9.9 GlaxoSmithKline plc
• 9.10 Henry Schein, Inc.
• 9.11 Hoffmann-La Roche Ltd.
• 9.12 Johnson & Johnson Services, Inc.
• 9.13 Kaken Pharmaceutical Co., Ltd.
• 9.14 Pfizer Inc.
• 9.15 Procter & Gamble Co.
• 9.16 Straumann Holding AG
• 9.17 Sunstar Suisse SA
• 9.18 Teva Pharmaceutical Industries Ltd.
• 9.19 Zimmer Biomet Holdings, Inc.
• 9.20 3M Company